Report cover image

Global Neuroendocrine Tumor Treatment Market Size Study, By Type (Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma), By Product (Somatostatin Analogs, Targeted Therapy, Others), By Site (Lung, Pancreas, Small Intestine, Stomach, Others), By En

Publisher Bizwit Research & Consulting
Published Jan 13, 2025
Length 285 Pages
SKU # BIZW19503013

Description

Global Neuroendocrine Tumor Treatment Market Size Study, By Type (Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma), By Product (Somatostatin Analogs, Targeted Therapy, Others), By Site (Lung, Pancreas, Small Intestine, Stomach, Others), By End Use (Hospitals, Clinics, Others), and Regional Forecasts 2022-2032


The global neuroendocrine tumor treatment market was valued at USD 2.51 billion in 2023 and is projected to grow at a CAGR of 6.0% during the forecast period 2024-2032, reaching a market size of USD 4.24 billion by 2032. This growth is primarily attributed to the increasing prevalence of neuroendocrine tumors, advancements in treatment modalities, and rising awareness among healthcare professionals and patients.

The escalating incidence of neuroendocrine tumors has spurred significant demand for innovative and effective treatment solutions. In the United States alone, over 12,000 new cases of neuroendocrine tumors are diagnosed annually, reflecting a growing need for advanced diagnostic tools and therapies. Additionally, breakthroughs such as Peptide Receptor Radionuclide Therapy (PRRT) are transforming the treatment landscape by enhancing therapeutic efficacy with fewer side effects compared to traditional methods.

Targeted therapies, especially Somatostatin Analogs (SSAs), have emerged as key contributors to market growth due to their proven ability to manage symptoms and control tumor progression. Pharmaceutical companies are heavily investing in research and development (R&D) to develop precision medicine solutions tailored to individual patient profiles, improving outcomes and fostering further innovation within the neuroendocrine tumor treatment industry.

Regional analysis reveals that North America dominated the market in 2024, holding a significant 42.1% revenue share, supported by advanced healthcare infrastructure and strong R&D activities. The Asia Pacific region is poised to witness the fastest growth rate due to expanding healthcare investments, growing awareness, and improved access to cutting-edge therapies in emerging economies such as China, India, and Japan.

Moreover, the rising adoption of outpatient care models has fueled growth within clinics, which are projected to grow at the highest CAGR over the forecast period. Patients increasingly prefer outpatient treatments for convenience, reduced costs, and shorter recovery periods, further driving the demand for advanced therapies.

Major Market Players Included in This Report
• Novartis AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Hutchison MediPharma Limited
• AVEO Pharmaceuticals, Inc.
• Ipsen Pharma
• Eli Lilly and Company
• Exelixis, Inc.
• Jubilant Pharmova Limited
• Advanced Accelerator Applications
• AstraZeneca PLC
• Merck & Co., Inc.
• Roche Holding AG
• Medtronic PLC

The Detailed Segments and Sub-Segments of the Market Are Explained Below

By Type:
• Meningiomas
• Adrenal Cancer
• Carcinoid Tumors
• Paraganglioma
• Pheochromocytoma
• Others

By Product:
• Somatostatin Analogs (SSAs)
• Targeted Therapy
• Others

By Site:
• Lung
• Pancreas
• Small Intestine
• Stomach
• Colon
• Rectum
• Others

By End Use:
• Hospitals
• Clinics
• Others

By Region:
• North America
U.S.
Canada
Mexico
• Europe
UK
Germany
France
Italy
Spain
Norway
Denmark
Sweden
• Asia Pacific
Japan
China
India
South Korea
Australia
Singapore
• Latin America
Brazil
Argentina
• Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait

Years Considered for the Study
• Historical Year: 2022
• Base Year: 2023
• Forecast Period: 2024-2032

Key Takeaways:
• Rising prevalence of neuroendocrine tumors and advancements in targeted therapies are driving market growth.
• North America holds the largest share, while Asia Pacific is expected to grow at the fastest pace.
• Somatostatin Analogs (SSAs) dominate the product segment, driven by their efficacy in managing tumor progression.
• Increasing preference for outpatient care and investments in precision medicine are key growth drivers.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

285 Pages
Chapter 1. Global Neuroendocrine Tumor Treatment Market Executive Summary
1.1. Global Neuroendocrine Tumor Treatment Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Type
1.3.2. By Product
1.3.3. By Site
1.3.4. By End Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Neuroendocrine Tumor Treatment Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Neuroendocrine Tumor Treatment Market Dynamics
3.1. Market Drivers
3.1.1. Increasing prevalence of neuroendocrine tumors
3.1.2. Advancements in targeted therapies and precision medicine
3.1.3. Rising R&D investments in oncology
3.2. Market Challenges
3.2.1. High cost of treatments and diagnostic tools
3.2.2. Limited awareness in emerging regions
3.3. Market Opportunities
3.3.1. Emerging healthcare infrastructure in Asia Pacific and Latin America
3.3.2. Technological advancements in diagnostic imaging and therapies
Chapter 4. Global Neuroendocrine Tumor Treatment Market Industry Analysis
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Key Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Neuroendocrine Tumor Treatment Market Size & Forecast by Type, 2022-2032
5.1. Segment Dashboard
5.2. Global Neuroendocrine Tumor Treatment Market Revenue Trend Analysis, 2022-2032 (USD Billion)
5.2.1. Meningiomas
5.2.2. Adrenal Cancer
5.2.3. Carcinoid Tumors
5.2.4. Paraganglioma
5.2.5. Pheochromocytoma
5.2.6. Others
Chapter 6. Global Neuroendocrine Tumor Treatment Market Size & Forecast by Product, 2022-2032
6.1. Segment Dashboard
6.2. Global Neuroendocrine Tumor Treatment Market Revenue Trend Analysis, 2022-2032 (USD Billion)
6.2.1. Somatostatin Analogs (SSAs)
6.2.2. Targeted Therapy
6.2.3. Others
Chapter 7. Global Neuroendocrine Tumor Treatment Market Size & Forecast by Site, 2022-2032
7.1. Segment Dashboard
7.2. Global Neuroendocrine Tumor Treatment Market Revenue Trend Analysis, 2022-2032 (USD Billion)
7.2.1. Lung
7.2.2. Pancreas
7.2.3. Colon
7.2.4. Small Intestine
7.2.5. Rectum
7.2.6. Stomach
7.2.7. Others
Chapter 8. Global Neuroendocrine Tumor Treatment Market Size & Forecast by End Use, 2022-2032
8.1. Segment Dashboard
8.2. Global Neuroendocrine Tumor Treatment Market Revenue Trend Analysis, 2022-2032 (USD Billion)
8.2.1. Hospitals
8.2.2. Clinics
8.2.3. Others
Chapter 9. Global Neuroendocrine Tumor Treatment Market Size & Forecast by Region, 2022-2032
9.1. North America
9.1.1. U.S.
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. UK
9.2.2. Germany
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Norway
9.2.7. Denmark
9.2.8. Sweden
9.3. Asia Pacific
9.3.1. Japan
9.3.2. China
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Singapore
9.4. Latin America
9.4.1. Brazil
9.4.2. Argentina
9.5. Middle East & Africa
9.5.1. South Africa
9.5.2. Saudi Arabia
9.5.3. UAE
9.5.4. Kuwait
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Novartis AG
10.1.2. Pfizer Inc.
10.1.3. Bristol-Myers Squibb Company
10.2. Top Market Strategies
10.3. Company Profiles
Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, and others.
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
List of Tables
1. Global Neuroendocrine Tumor Treatment Market Size Estimates, 2022-2032
2. By Type - Meningiomas, Adrenal Cancer, Carcinoid Tumors Revenue Trends (USD Billion)
3. By Product - Somatostatin Analogs, Targeted Therapy Revenue Trends
4. By Site - Lung, Pancreas, Colon, Small Intestine, Stomach Revenue Trends
5. By End Use - Hospitals, Clinics, Others Revenue Trends
6. North America Market Estimates, By Country, 2022-2032
7. Europe Market Estimates, By Country, 2022-2032
8. Asia Pacific Market Estimates, By Country, 2022-2032
9. Latin America Market Estimates, By Country, 2022-2032
10. MEA Market Estimates, By Country, 2022-2032
Note: This list is not complete; the final report contains more than 100 tables. The list may be updated in the final deliverable.
List of Figures
1. Global Neuroendocrine Tumor Treatment Market Dynamics
2. Market Segmentation by Type, Product, Site, End Use, and Region
3. Regional Analysis Snapshot - North America, Europe, Asia Pacific
4. Competitive Landscape Analysis, 2022-2032
5. Key Trends in Neuroendocrine Tumor Treatment Market
6. R&D Investments by Key Players
7. Global Revenue Contribution by Type and Product
Note: This list is not complete; the final report contains more than 50 figures. The list may be updated in the final deliverable.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us